^
1d
Socioeconomic Disparities in Breast Cancer Survival: Examining Potential Mediator Role of Oncotype DX(ODX) Test and Stage at Diagnosis Among HR+/HER2- Breast Cancer Women. (PubMed, Cancers (Basel))
Low SES is associated with higher hazard rates of overall and cause-specific death among women with breast cancer, even after adjustment. Differences in Oncotype DX (ODX) testing and stage at diagnosis explained part of these disparities. Targeted interventions are needed to improve access to genomic testing and early detection to reduce SES-related disparities in breast cancer outcomes.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Oncotype DX Breast Recurrence Score®Test
7d
Retrospective data • Review • Journal
|
ER (Estrogen receptor)
|
ER positive
|
Oncotype DX Breast Recurrence Score®Test
9d
External validation of the Oncotype DX breast cancer recurrence score nomogram and development and validation of a novel machine learning-based model to predict postoperative overall survival and guide adjuvant chemotherapy in ER positive, Her-2 negative breast cancer patients: a retrospective cohort study. (PubMed, Front Oncol)
The AORSF has the potential to identify postoperative OS and guide ACT in patients with BC. This can assist clinicians in assessing the severity of the disease, facilitating patient follow-up, and aiding in the formulation of adjuvant treatment strategies.
Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • HER-2 negative + ER positive
|
Oncotype DX Breast Recurrence Score®Test
11d
A mixed-methods study characterizing experiences of medical oncologists' use of gonadotropin-releasing hormone agonists for treatment of breast cancer. (PubMed, Breast Cancer Res Treat)
Oncologists reported strong agreement with established guidelines for the use of OFS in the treatment of early-stage hormone receptor-positive breast cancer. However, our findings indicate a need for guidance regarding the determination of menopausal status in the setting of amenorrhea and monitoring of ovarian function.
Journal
|
HR positive
|
Oncotype DX Breast Recurrence Score®Test
14d
Ki-67 and 21-gene recurrence score assay in decision making for adjuvant chemotherapy in breast cancer patients. (PubMed, Discov Oncol)
These challenges have ignited researchers to evaluate genomic signatures, which has led to the introduction of several genomic tests that can now help oncologists to include/exclude chemotherapy from the treatment regimen with more confidence. The present review aims to look back over the literature on the clinical significance of Ki-67 as well as the 21-gene recurrence score assay in identification of breast cancer patients who may benefit from the adjuvant chemotherapy.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
Oncotype DX Breast Recurrence Score®Test
15d
PDxBRUTILITY: Decision Impact Study of PreciseDx Breast (clinicaltrials.gov)
P=N/A, N=300, Not yet recruiting, Precise Dx, Inc. | Trial primary completion date: May 2025 --> Aug 2026
Trial primary completion date
|
MammaPrint • Oncotype DX Breast Recurrence Score®Test
17d
Metastatic breast cancer through the Oncotype DX Breast Recurrence Score®: insights from a small cohort study. (PubMed, Breast Cancer Res Treat)
RS generation from metastatic biopsy samples was feasible in 46% of cases. Results revealed higher RS in metastatic disease, frequent PR loss, and poor correlation with primary tumors. Adequate tissue sampling is essential for improving RNA quality and test success. Further research into RS result relevance in metastatic treatment decisions is warranted.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HR positive • HER-2 negative • HER-2 expression
|
Oncotype DX Breast Recurrence Score®Test
17d
Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers. (PubMed, Cancer)
SLNB omission has a small - but not negligible - influence on adjuvant decision making in postmenopausal women, whereas a larger proportion of premenopausal women would be impacted. The reported estimates may inform multidisciplinary decision-making related to SLNB omission.
Journal
|
HR positive
|
Oncotype DX Breast Recurrence Score®Test
|
Kisqali (ribociclib)
17d
The Value of Routine Reflex In Situ Hybridization Testing in Low-grade Tubule-forming Invasive Breast Cancers With Equivocal HER2 Immunohistochemistry: A Reappraisal of the ASCO/CAP Guidelines. (PubMed, Appl Immunohistochem Mol Morphol)
In conclusion, HER2 amplification is rare in low-grade, tubule-forming IBCs. These results suggest reconsidering current guidelines to reduce unnecessary FISH testing, potentially improving cost-effectiveness and clinical efficiency without compromising diagnostic accuracy.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 amplification
|
Oncotype DX Breast Recurrence Score®Test
20d
Computer-Aided Diagnosis of ER-positive, HER2-Negative Breast Cancer on Dynamic Contrast-Enhanced MRI: Associations With Oncotype DX Recurrence Scores. (PubMed, Clin Breast Cancer)
Higher kinetic heterogeneity on CAD was associated with an increased risk of recurrence in patients with ER-positive, HER2-negative breast cancer.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • HER-2 negative + ER positive
|
Oncotype DX Breast Recurrence Score®Test
20d
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025 ()
"Exact Sciences Corp...today announced it will present ten abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30–June 3, 2025, in Chicago, Ill. Presentations include new data on the Oncodetect™ molecular residual disease (MRD) test, multi-cancer early detection (MCED) testing, the Oncotype DX Breast Recurrence Score® test, and the Cologuard® test that underscore Exact Sciences’ expanding portfolio and commitment to advancing care through scientific excellence."
Oncotype DX Breast Recurrence Score®Test
1m
Radiomics Analysis of Breast MRI to Predict Oncotype Dx Recurrence Score: Systematic Review. (PubMed, Diagnostics (Basel))
Multiparametric MRI-based models integrating multiple sequences have achieved the highest performance. While further validation is needed, MRI radiomics may offer a non-invasive, cost-effective alternative for assessing recurrence risk.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • EGFR positive
|
Oncotype DX Breast Recurrence Score®Test
1m
Gene Expression Signatures for Guiding Initial Therapy in ER+/HER2- Early Breast Cancer. (PubMed, Cancers (Basel))
Here, we review the published data on the most common gene expression signatures (MammaPrint (MP), BluePrint (BP), Oncotype Dx, PAM50, the Breast Cancer Index (BCI), and EndoPredict (EP)) and their ability to predict the response to neoadjuvant treatment, as well as the possibility of using them on core needle biopsies. Additionally, we review the changes in the gene expression signatures after neoadjuvant treatment, and the ongoing clinical trials related to the utility of gene expression signatures in the neoadjuvant setting.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER positive • HER-2 negative • EGFR positive • ER positive + HER-2 negative • HER-2 negative + ER positive
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • BluePrint • Breast Cancer Index® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
1m
Optimization of guidelines for Risk Of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study. (PubMed, Breast)
Machine learning algorithms can enhance patient selection for gene expression profiling, though further external validation is needed.
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • Oncotype DX Breast Recurrence Score®Test
1m
High Ki-67 expression is associated with increased risk of distant recurrence in Oncotype Dx low risk breast cancer. (PubMed, Clin Breast Cancer)
Ki-67 expression level may help to identify a subset of low risk Oncotype Dx patients who could benefit from adjuvant chemotherapy.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
Oncotype DX Breast Recurrence Score®Test
1m
Additional prognostic value of the BCT score in ER+HER2- breast cancer patients receiving a 21-gene assay-guided adjuvant treatments. (PubMed, Front Oncol)
In addition, the RFS of the low-BCT score group was superior to that of the high-BCT group in women aged 50 years or younger, with an RS of 16 to 25. Our study suggests the utility of the BCT score in stratifying the relapse risk among chemotherapy-untreated patients with a low RS, particularly in young women with an RS of 16-25 who are at risk for long-term recurrence.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 negative
|
Oncotype DX Breast Recurrence Score®Test
2ms
Refining prognostic tools for luminal breast cancer: genetic insights and comprehensive analysis. (PubMed, ESMO Open)
Our study reveals key genetic factors associated with recurrence risk in luminal BC. Identifying these mutations and copy number alterations provides a basis for refined prognostic models and suggests avenues for further research, potentially improving treatment strategies and follow-up care for patients with luminal BC.
Journal • BRCA Biomarker
|
TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA2 (Breast cancer 2, early onset) • RB1 (RB Transcriptional Corepressor 1) • KMT2C (Lysine Methyltransferase 2C) • CDH1 (Cadherin 1) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22)
|
TP53 mutation • PIK3CA mutation
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • Oncotype DX Breast Recurrence Score®Test
2ms
Applying a novel measure of community-level healthcare access to assess breast cancer care timeliness. (PubMed, Cancer Epidemiol Biomarkers Prev)
Policy efforts to improve access in communities should consider multiple dimensions of access including geospatial accessibility and affordability.
Journal
|
Oncotype DX Breast Recurrence Score®Test
2ms
Oncotype DX Recurrence Score and Germline BRCA Variants in Patients with HR-Positive/HER2-Negative Early Breast Cancer: A Retrospective Observational Study. (PubMed, Oncol Ther)
Prevalence of gBRCA PV was highest among patients with high tumor RS, but not negligible in patients with intermediate and low tumor RS. Wider implementation of genetic testing, irrespective of ODX RS, could help optimize the management of patients with HR-positive/HER2-negative early breast cancer.
Observational data • Retrospective data • Journal • BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
HER-2 positive • HR positive • HER-2 negative • EGFR positive • HR positive + HER-2 negative
|
Oncotype DX Breast Recurrence Score®Test
2ms
Characteristics of premenopausal breast cancer patients with a midrange 21-gene recurrence score. (PubMed, Ann Surg Treat Res)
In the premenopausal patients with a midrange ODx, considering the baseline characteristic itself, there was a significant difference between those with a low ODx when compared with postmenopausal patients. Therefore, more aggressive treatment decisions may be helpful in premenopausal patients with a midrange ODx.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • EGFR positive
|
Oncotype DX Breast Recurrence Score®Test
2ms
JAMA Oncology Publication Strengthens Evidence for Oncotype DX Test Reliability Across Racial and Ethnic Groups (Businesswire)
"Exact Sciences Corp....today announced the publication of a comprehensive review in JAMA Oncology that strengthens the evidence supporting the Oncotype DX Breast Recurrence Score test. The peer-reviewed article titled, 'Genomic Assays for Breast Cancer in Diverse Populations: Prognostic and Predictive Insights,' affirms that the Oncotype DX test provides accurate and reliable information to help guide breast cancer treatment decisions across all racial and ethnic groups....'This study helps deepen our understanding of the multifaceted factors driving disparities in breast cancer outcomes,'...This publication reinforces the Oncotype DX test’s value in helping guide treatment decisions—providing precise estimates of distant recurrence risk and accurately identifying which breast cancer patients may or may not benefit from chemotherapy, regardless of race or ethnicity."
Clinical
|
Oncotype DX Breast Recurrence Score®Test
2ms
Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study. (PubMed, Eur J Cancer)
Recurrence Score result significantly impacts treatment decisions in HR+ /HER2-EBC. RS result was not associated with BMI, although unfavorable metabolic profiles and obesity-related markers correlated with larger tumors. These findings highlight the need to further investigate the link between metabolic profiles and breast cancer biology.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • LEP (Leptin)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
Oncotype DX Breast Recurrence Score®Test
2ms
CTRIAL-IE (ICORG) 15-34: The impact of the 21 gene breast recurrence score® assay on chemotherapy prescribing in oestrogen receptor positive, lymph node positive early stage breast cancer in Ireland. (PubMed, Ir J Med Sci)
Consistent with our hypothesis, broader access to the Recurrence Score® led to a reduction in the use of chemotherapy in Ireland and has subsequently become standard of care.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive
|
Oncotype DX Breast Recurrence Score®Test
2ms
New P4 trial
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
|
Oncotype DX Breast Recurrence Score®Test
2ms
HER2 mRNA Score From Quantitative ERBB2 mRNA Expression of Oncotype Dx: Can It Replace the HER2 Immunohistochemistry? (PubMed, Am J Surg Pathol)
After defining 8.9 as a suboptimal cutoff mRNA score, multivariate analysis revealed that low Ki-67 (8.9), whereas progesterone receptor negativity, high Ki-67, high nuclear grade, lower HS, and older age (>50 y) were statistically associated with high RS. Our study revealed that HS is significantly associated with HER2 IHC results and clinicopathologic parameters other than HER2 IHC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER positive • HER-2 negative • HER-2 expression • HER-2 negative + ER positive
|
Oncotype DX Breast Recurrence Score®Test
3ms
Improving patient understanding of GEP test results (IMPARTER4): an RCT. (PubMed, BMJ Oncol)
Patients who received standard verbal and written information plus film had increased knowledge about GEP tests compared with standard information alone. ISRCTN28497350.
Journal
|
ER (Estrogen receptor)
|
ER positive
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • Oncotype DX Breast Recurrence Score®Test
3ms
IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses. (PubMed, Breast Cancer)
This study offers new validation analyses of IRSN-23 in predicting chemotherapy efficacy, showing high reproducibility. The findings indicate the clinical value of using IRSN-23 for refining breast cancer subtype classification, with implications for personalized treatment strategies and improved patient outcomes.
Journal
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • Oncotype DX Breast Recurrence Score®Test
|
Herceptin (trastuzumab) • paclitaxel
3ms
New trial
|
Oncotype DX Breast Recurrence Score®Test
3ms
Nomogram Development for Assessing Oncotype DX Recurrence Scores in Breast Cancer: A Chinese Population Study. (PubMed, Cancer Med)
We present the first nomogram for predicting the RS in Chinese patients with BC on the basis of clinicopathological factors. This model could aid in identifying patients who may not need ODX testing and serve as a cost-effective alternative for those unable to access ODX, thereby optimizing treatment decisions and enhancing patient management in resource-limited settings.
Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • HER-2 negative + ER positive
|
Oncotype DX Breast Recurrence Score®Test
3ms
First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers? (PubMed, Cancer Treat Rev)
We focus on studies that directly compare these molecular tests and discuss how their strengths can be leveraged to improve clinical decision-making for early-stage HR+ breast cancers. Finally, we highlight remaining knowledge gaps and propose directions for future research.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • Oncotype DX Breast Recurrence Score®Test
3ms
Breast Cancer: A Heterogeneous Pathology. Prognostic and Predictive Factors - A Narrative Review. (PubMed, Chirurgia (Bucur))
Moreover, the implementation of Molecular Tumor Boards further enhances personalized treatment strategies, contributing to improved patient outcomes and survival rates. This review underscores the significance of tailored therapeutic approaches and highlights the dynamic evolution of breast cancer in clinical practice.
Review • Journal • BRCA Biomarker
|
TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • PALB2 (Partner and localizer of BRCA2)
|
TP53 mutation • PIK3CA mutation • PTEN mutation • PALB2 mutation
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
3ms
Current controversies in the use of Oncotype DX in early breast cancer. (PubMed, Cancer Treat Rev)
Oncotype DX® is a broadly utilized genomic test for breast cancer, having the highest level of supporting evidence to inform clinical practice. Our manuscript provides a comprehensive overview on this recurrence score assay, evaluates supporting evidence across patient populations, and discusses their impact on treatment decisions in those groups of patients underrepresented in pivotal clinical trials, where evidence is limited with the use of Oncotype DX.
Review • Journal
|
Oncotype DX Breast Recurrence Score®Test
3ms
Utilization and Outcomes of the 21-Gene Recurrence Score in pN2 Breast Cancer Patients. (PubMed, Anticancer Res)
Despite the underutilization of chemotherapy for hormone receptor-positive, Her2-negative, pN2 patients, it was associated with improved OS for all 21-gene panel risk groups. These results support the existing standard of chemotherapy for this population, although omission could be considered in patients over 70 years of age.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
Oncotype DX Breast Recurrence Score®Test
3ms
Oncotype DX recurrence score in node-positive patients in the post-RxPONDER era: a single-institution experience. (PubMed, Breast Cancer Res Treat)
ODX RS distribution among LN + and LN- women aged ≥ 50y was similar. In this population, RS is significantly associated with tumor grade, ER, and PR, regardless of LN status. In our post-RxPONDER era cohort, over 80% of women aged ≥ 50y with early-stage ER + /HER2- BC with ≤ 3 positive axillary LN would be spared chemotherapy based on RS, regardless of nodal status.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Oncotype DX Breast Recurrence Score®Test
3ms
Multimodal histopathologic models stratify hormone receptor-positive early breast cancer. (PubMed, Nat Commun)
Furthermore, in patients with RS ≤ 25, Orpheus ascertains risk of metastatic recurrence more accurately than the RS itself (0.75 vs 0.49 mean time-dependent AUC). These findings have the potential to guide adjuvant therapy for high-risk cases and tailor surveillance for patients at elevated metastatic recurrence risk.
Journal
|
HR positive
|
Oncotype DX Breast Recurrence Score®Test
4ms
Probability of OncotypeDx to Reallocate As Low or High Risk of Recurrence Breast Cancer Patients with Uncertain Biology (clinicaltrials.gov)
P=N/A, N=258, Completed, Fondazione Sandro Pitigliani | Active, not recruiting --> Completed
Trial completion
|
Oncotype DX Breast Recurrence Score®Test
4ms
Genetic Ancestry and 21-Gene Oncotype DX Breast Cancer Recurrence Scores. (PubMed, Ann Surg Oncol)
Increasing West African ancestry is associated with increased odds of high and intermediate RS, while increasing East Asian ancestry is associated with lower odds of intermediate RS. These findings require validation but suggest ancestry may represent a biological biomarker and that assays guiding adjuvant therapy may require ancestry-based calibration in HR+/HER2- tumors.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HR positive • HER-2 negative • HER-2 expression • EGFR positive
|
Oncotype DX Breast Recurrence Score®Test
4ms
New P2 trial
|
BRCA (Breast cancer early onset)
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • Oncotype DX Breast Recurrence Score®Test
|
Keytruda (pembrolizumab) • carboplatin • paclitaxel
4ms
MRI biomarkers and their correlation with the Oncotype DX test. (PubMed, Radiologia (Engl Ed))
The aim of this article is to review knowledge regarding MRI biomarkers to date according to the BI-RADS® classification and the use of artificial intelligence (AI) in this imaging technique to establish its correlation with the ODXRS test. The latest studies published on AI and MRI present promising findings, and their standardisation could mark a turning point in breast radiology.
Review • Journal
|
Oncotype DX Breast Recurrence Score®Test
4ms
Evaluation and Comparison of Prognostic Multigene Tests in Early-Stage Breast Cancer: Which Is the Most Effective? A Literature Review Exploring Clinical Utility to Enhance Therapeutic Management in Luminal Patients. (PubMed, Mol Carcinog)
While multiple gene expression profiling tests are available, they classify patients differently and are not interchangeable; therefore, their application should be at the clinician's discretion during the decision-making process. It is essential that these tests are not the sole factor in determining the best treatment plan: other clinical considerations and patient preferences should also play a significant role in guiding treatment decisions.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • Breast Cancer Index® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
4ms
HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN. (PubMed, Breast Cancer Res)
The prevalence of HER2-low status varied between the analyzed trials. Our results show that survival does not differ between HER2-low and HER2-zero tumors in HR + /HER2- cohorts; however, HER2-low status appears to have an inconsistent impact on survival in TNBC. Therefore, our findings do not support the characterization of HER2-low status as a distinct BC subtype.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 negative
|
Oncotype DX Breast Recurrence Score®Test
4ms
The Optimal Treatment of Invasive Ductal and Lobular Carcinoma Occurring at the same time needs to be Established. (PubMed, Eur J Case Rep Intern Med)
The optimal treatment of synchronous bilateral breast cancers with differing histological subtypes remains uncertain.This case illustrates the importance of leveraging existing evidence, multidisciplinary collaboration and patient-centred decision-making when addressing knowledge gaps.There is a call for further research to establish guidelines for managing simultaneous, histologically distinct breast cancers.
Journal • BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 negative + AR positive + ER positive
|
Oncotype DX Breast Recurrence Score®Test • Oncotype DX® Colon Recurrence Score test